Has the Optimal Therapy for Invasive Candidiasis Now Been Defined?

被引：4
作者：
Andes, David [1 ]
机构：
[1] Univ Wisconsin, Dept Med & Microbiol & Immunol, 1685 Highland Ave, Madison, WI 53705 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2019年 / 68卷 / 12期
关键词：
AMPHOTERICIN-B; COMPARING FLUCONAZOLE; CANDIDAL INFECTIONS; ANTIFUNGAL AGENTS; RANDOMIZED-TRIAL; VORICONAZOLE; MULTICENTER; MICAFUNGIN; ISAVUCONAZOLE; EPIDEMIOLOGY;
D O I：
10.1093/cid/ciy830
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1990 / 1992
页数：3
相关论文
共 31 条
  • [1] A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients
    AbeleHorn, M
    Kopp, A
    Sternberg, U
    Ohly, A
    Dauber, A
    Russwurm, W
    Buchinger, W
    Nagengast, O
    Emmerling, P
    [J]. INFECTION, 1996, 24 (06) : 426 - 432
  • [2] Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature
    Anaissie, EJ
    Darouiche, RO
    AbiSaid, D
    Uzun, O
    Mera, J
    Gentry, LO
    Williams, T
    Kontoyiannis, DP
    Karl, CL
    Bodey, GP
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (05) : 964 - 972
  • [3] The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)
    Andes, David R.
    Safdar, Nasia
    Baddley, John W.
    Alexander, Barbara
    Brumble, Lisa
    Freifeld, Allison
    Hadley, Susan
    Herwaldt, Loreen
    Kauffman, Carol
    Lyon, G. Marshall
    Morrison, Vicki
    Patterson, Thomas
    Perl, Trish
    Walker, Randall
    Hess, Tim
    Chiller, Tom
    Pappas, Peter G.
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2016, 18 (06) : 921 - 931
  • [4] Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials
    Andes, David R.
    Safdar, Nasia
    Baddley, John W.
    Playford, Geoffrey
    Reboli, Annette C.
    Rex, John H.
    Sobel, Jack D.
    Pappas, Peter G.
    Kullberg, Bart Jan
    [J]. CLINICAL INFECTIOUS DISEASES, 2012, 54 (08) : 1110 - 1122
  • [5] Bosch B, 2016, NEW ENGL J MED, V374, P794, DOI 10.1056/NEJMc1514201
  • [6] Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans
    Ernst, EJ
    Klepser, ME
    Pfaller, MA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) : 1108 - 1111
  • [7] Treatment of invasive candidal infections: Systematic review and meta-analysis
    Gafter-Gvili, Anat
    Vidal, Liat
    Goldberg, Elad
    Leibovici, Leonard
    Paul, Mical
    [J]. MAYO CLINIC PROCEEDINGS, 2008, 83 (09) : 1011 - 1021
  • [8] Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study
    Garey, Kevin W.
    Rege, Milind
    Pai, Manjunath P.
    Mingo, Dana E.
    Suda, Katie J.
    Turpin, Robin S.
    Bearden, David T.
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (01) : 25 - 31
  • [9] Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials
    Horn, D. L.
    Ostrosky-Zeichner, L.
    Morris, M. I.
    Ullmann, A. J.
    Wu, C.
    Buell, D. N.
    Kovanda, L. L.
    Cornely, O. A.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2010, 29 (02) : 223 - 229
  • [10] Septic Shock Attributed to Candida Infection: Importance of Empiric Therapy and Source Control
    Kollef, Marin
    Micek, Scott
    Hampton, Nicholas
    Doherty, Joshua A.
    Kumar, Anand
    [J]. CLINICAL INFECTIOUS DISEASES, 2012, 54 (12) : 1739 - 1746
1234